BioCentury | Dec 24, 2012
Company News

Sygnis Pharma diagnostic news

Sygnis said it will reduce headcount by 10 (30%) to 23 and discontinue its KIBRA R&D project. The company said it was not possible to out-license the project within the available timeline and the project...
BioCentury | Dec 19, 2011
Company News

Roche management update

Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Pharmaceuticals Transitioning: Head of Roche Partnering Dan Zabrowski to head of Roche applied science in the pharma's diagnostics division, effective Feb. 1, 2012; Sophie Kornowski-Bonnet, who is general manager...
BioCentury | Dec 16, 2011
Company News

Roche shuffles management

Roche (SIX:ROG; OTCQX:RHHBY) said Head of Roche Partnering Dan Zabrowski will become head of Roche applied science in the pharma's diagnostics division, effective Feb. 1. Sophie Kornowski-Bonnet, who is general manager of Roche Pharma in...
BioCentury | May 30, 2011
Finance

Europe's Iceberg 2011: Unlocking hidden value

The European biotech industry is now about a generation old - long enough for investors and managements to benefit from the experiences of several business cycles. While it is easy to complain about the flaws in...
BioCentury | May 18, 2009
Strategy

Genentech's staying power

An exodus of employees from Genentech Inc. - widely assumed to be inevitable now that the biotech is fully owned by Roche - may turn out to be slower than expected as a result of some shrewd...
BioCentury | Jan 26, 2009
Regulation

MDx: A murky brew

The gaps and overlaps in the regulatory environment surrounding molecular diagnostics are becoming more glaring as more complicated genetic tests make their way to market. The regulatory setting now has been further clouded by a...
Items per page:
1 - 6 of 6
BioCentury | Dec 24, 2012
Company News

Sygnis Pharma diagnostic news

Sygnis said it will reduce headcount by 10 (30%) to 23 and discontinue its KIBRA R&D project. The company said it was not possible to out-license the project within the available timeline and the project...
BioCentury | Dec 19, 2011
Company News

Roche management update

Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Pharmaceuticals Transitioning: Head of Roche Partnering Dan Zabrowski to head of Roche applied science in the pharma's diagnostics division, effective Feb. 1, 2012; Sophie Kornowski-Bonnet, who is general manager...
BioCentury | Dec 16, 2011
Company News

Roche shuffles management

Roche (SIX:ROG; OTCQX:RHHBY) said Head of Roche Partnering Dan Zabrowski will become head of Roche applied science in the pharma's diagnostics division, effective Feb. 1. Sophie Kornowski-Bonnet, who is general manager of Roche Pharma in...
BioCentury | May 30, 2011
Finance

Europe's Iceberg 2011: Unlocking hidden value

The European biotech industry is now about a generation old - long enough for investors and managements to benefit from the experiences of several business cycles. While it is easy to complain about the flaws in...
BioCentury | May 18, 2009
Strategy

Genentech's staying power

An exodus of employees from Genentech Inc. - widely assumed to be inevitable now that the biotech is fully owned by Roche - may turn out to be slower than expected as a result of some shrewd...
BioCentury | Jan 26, 2009
Regulation

MDx: A murky brew

The gaps and overlaps in the regulatory environment surrounding molecular diagnostics are becoming more glaring as more complicated genetic tests make their way to market. The regulatory setting now has been further clouded by a...
Items per page:
1 - 6 of 6